A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
NCT ID: NCT03047889
Last Updated: 2017-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
4200 participants
OBSERVATIONAL
2016-04-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China
NCT02493569
Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China
NCT04076111
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
NCT03381092
A Study Comparing the Differences Between Young and Non-young Breast Cancer
NCT06793306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
standard therapy
standard therapy for advanced/metastatic breast cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.
Exclusion Criteria
18 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Binghe Xu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Binghe Xu
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences
Youlin Qiao
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The 307th Hospital of Military Medical Sciences
Beijing, , China
Sichuan Cancer Hospital and Institute
Chengdu, , China
The First Affliated Hospital of Chongqing Medical University
Chongqing, , China
FuZhou General Hospital of National Miltary Command
Fuzhou, , China
Sun Yat-Sen University Cancer Center
Guangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Henan Cancer Hospital
Henan, , China
Hunan Cancer Hospital
Hunan, , China
Jiangsu Provinces hospital
Jiangsu, , China
Tumor Hospital of Yunnan Province
Kunming, , China
Liaoning Cancer Hospital, Zhejiang Cancer Hospital
Liaoning, , China
General Hospital of NingXia Medical University
Ningxia, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
The First Hospital of China Medical University
Shenyang, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, , China
Wuhan Union Hospital
Wuhan, , China
The First Hospital of Xi'an Jiaotong University
Xi'an, , China
Xinjiang Medical University Cancer Hospital
Xinjiang, , China
FuJian Provincial Cancer Hospital
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zefei Jiang
Role: primary
Hui Li
Role: primary
Hongyuan Li
Role: primary
Xuenong Ouyang
Role: primary
Shuseng Wang
Role: primary
Li Cai
Role: primary
Min Yan
Role: primary
Quchang Ouyang
Role: primary
Yongmei Yin
Role: primary
Runxiang Yang
Role: primary
Tao Sun
Role: primary
Xinlan Liu
Role: primary
Xichun Hu
Role: primary
Yuee Teng
Role: primary
Zhongsheng Tong
Role: primary
Tao Huang
Role: primary
Jianjun He
Role: primary
Shune Yang
Role: primary
Jian Liu
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol. 2021 Sep 15;2021:6621722. doi: 10.1155/2021/6621722. eCollection 2021.
Guo F, Yi Z, Wang W, Han Y, Yu P, Zhang S, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Fan J, Qiao Y, Wang J, Xu B. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer Med. 2021 Oct;10(19):6744-6761. doi: 10.1002/cam4.4215. Epub 2021 Sep 2.
Wu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J, Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb 11;10:599604. doi: 10.3389/fonc.2020.599604. eCollection 2020.
Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021 Feb 1;148(3):692-701. doi: 10.1002/ijc.33227. Epub 2020 Aug 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CH-BC-045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.